HIGHLIGHTS
- who: Fabrizio Di Benedetto from the Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy have published the paper: Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature, in the Journal: (JOURNAL)
- what: In detail, this study showed that the median OS in the Everolimus arm was 7.56 months vs. 7.33 months in the placebo arm (p=0.675). The aim of this study is to determine the safety and efficacy of this therapeutic regimen in patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.